Award

Defining the role of APOE secreted from senescent fibroblasts in lung adenocarcinoma

Description: Lung cancer is one of the leading causes of cancer-related deaths in the United States. Tobacco smoking accounts for 90% of lung cancer deaths. Mutated KRAS is the predominant driver mutation in tobacco-related non-small cell lung cancer (NSCLC), which is not susceptible to the numerous tyrosine kinase inhibitors that target EGFR and other mutations commonly found in never smokers. A prominent feature of KRAS-induced NSCLC is the extensive remodeling of the tumor microenvironment (TME) that can drive tumor progression. Given that only a small fraction of lung cancer patients responds to therapies targeting oncogenic mutation and checkpoint blockade, tumor microenvironment can be a potential target to improve therapeutic efficacy. Stromal cells interact with cancer cells and other microenvironments in a dynamic manner. Studies show that cancer-associated fibroblasts (CAFs) have diverse functions based on phenotypic markers and gene expressions. Due to the heterogeneity of CAFs, it is important to identify and target specific subset of CAFs which contributes to progression and relapse of cancer. Cigarette smoke, the predominant cause of lung cancer, can also induce senescence in lung fibroblasts. Studies suggest that senescent fibroblasts may support cancer cell’s proliferation. However, it is unclear how the senescent fibroblasts affect cancer cell’s properties. Our research goal is to define the role of senescent fibroblasts in lung cancer development. Our lab has recently established a mouse model which can trace senescent cells. Our preliminary data shows that senescent CAFs are present in the tumor stroma of lung cancer. We also found that APOE, a secreted lipid binding protein, is highly expressed in senescent CAFs. Furthermore, our preliminary data show that APOE secreted by senescent CAFs can alter tumor lipid metabolism and promote tumor growth. This suggests that senescent CAF-derived APOE supports tumor progression by rewiring lipid metabolism in lung cancer. Our proposal aims to define how APOE alters tumor metabolic properties to promote growth, and how to target this pathway as a potential therapeutic target in lung cancer.
Amount: $324,800
Start date: 2023-07-01
Investigator: Jinyoung Lee (lead)
Subfield: Cell Biology
Funded outputs count: 0
Funder award ID: g9m56s
OpenAlex ID: G7162675325